<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00552097</url>
  </required_header>
  <id_info>
    <org_study_id>P02578</org_study_id>
    <nct_id>NCT00552097</nct_id>
  </id_info>
  <brief_title>Effect of Ezetimibe Plus Simvastatin Versus Simvastatin Alone on Atherosclerosis in the Carotid Artery (ENHANCE)(P02578)</brief_title>
  <acronym>ENHANCE</acronym>
  <official_title>Effect of Combination Ezetimibe and High-Dose Simvastatin vs Simvastatin Alone on the Atherosclerotic Process in Subjects With Heterozygous Familial Hypercholesterolemia (The ENHANCE Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether ezetimibe plus simvastatin will be more
      effective than simvastatin alone in preventing progression of atherosclerosis of the inner
      layer of the carotid artery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2002</start_date>
  <completion_date type="Actual">April 25, 2006</completion_date>
  <primary_completion_date type="Actual">April 25, 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ultrasound-determined average carotid artery intima-media thickness (IMT) on a per subject basis between baseline and endpoint.</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a reduction in ultrasound-determined average carotid artery IMT between baseline and endpoint.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ultrasound-determined maximum carotid artery IMT on a per subject basis between baseline and endpoint.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects developing new carotid artery plaques between baseline and endpoint.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ultrasound-determined average carotid artery plus average common femoral artery IMT on a per subject basis between baseline and endpoint.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">720</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Hyperlipoproteinemia Type II</condition>
  <arm_group>
    <arm_group_label>EZ/Simva</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Simva</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe (plus simvastatin)</intervention_name>
    <description>oral tablets; ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months</description>
    <arm_group_label>EZ/Simva</arm_group_label>
    <other_name>ZETIA</other_name>
    <other_name>VYTORIN</other_name>
    <other_name>SCH 58235</other_name>
    <other_name>SCH 465981</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo (plus simvastatin)</intervention_name>
    <description>tablets; placebo to match ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months</description>
    <arm_group_label>Placebo/Simva</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genotype-confirmed heterozygous familial hypercholesterolemia with written
             documentation of the genetic diagnosis at the time of screening and LDL-C &gt;=210 mg/dL
             (5.43 mmol/L), or clinical diagnosis of heterozygous familial hypercholesterolemia,
             defined as LDL-C &gt;=210 mg/dL (5.43 mmol/L) and at least one of the following:

               -  tendinous xanthoma

               -  child &lt;18 years of age with hypercholesterolemia (LDL-C &gt;159 mg/dL (4.11 mmol/L)

               -  has a sibling with hypercholesterolemia (LDL-C &gt;190 mg/dL [4.91 mmol/L]) and
                  tendinous xanthoma

               -  family history with an LDL-C value distribution pattern compatible with dominant
                  autosomal transmission and at least one relative presenting fasting total
                  cholesterol values &gt;348 mg/dL (9.0 mmol/L) after exclusion of secondary causes of
                  dyslipidemia

          -  LDL-C &gt;=210 mg/dL (5.43 mmol/L) 1 week before randomization

          -  plasma triglyceride level &lt;=400 mg/dL (4.52 mmol/L)

        Exclusion Criteria:

          -  pregnancy or any other situation, condition, or illness that, in the opinion of the
             investigator, may interfere with optimal participation in the study

          -  presence of an apolipoprotein B gene mutation with confirmed absence of an LDL
             receptor mutation in either allele

          -  undergoing LDL-apheresis or plasma apheresis

          -  unsuitable plaque or artery morphology

          -  use of certain drugs, foods, or other agents known to alter cholesterol levels or to
             cause pharmacokinetic interactions with either ezetimibe or simvastatin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Kastelein JJ, Sager PT, de Groot E, Veltri E. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am Heart J. 2005 Feb;149(2):234-9.</citation>
    <PMID>15846260</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2007</study_first_submitted>
  <study_first_submitted_qc>October 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2007</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

